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THE EFFECT OF IMMUNOSUPPRESSIVE DRUGS ON QUALITY 
OF LIFE AFTER RENAL TRANSPLANTATION
L u k a s  B. H il b r a n d s ,1,2 A n d r ie s  J . H o it sm a , a n d  R o be r t  A.P. K o e n u
Department of Medicine, Division o f  Nephrology, University H ospital Nijmegen, NL-6500 H B Nijmegen , The N etherlands
This prospective, randomized study investigates the 
effect of two immunosuppressive treatment regimens 
on quality of life after renal transplantation. At 3 
months after transplantation, patients treated with 
cyclosporine (CsA) and prednisone (Pred) were allo­
cated to either withdrawal of Pred (n=60) or to con­
version of CsA to azathioprine (Aza) (Aza-Pred, n=60). 
Quality of life was evaluated just before randomiza­
tion, and at 6 and 12 months after transplantation 
using the Sickness Impact Profile (SIP), the Affect Bal­
ance Scale (ABS), the Center for Epidemiological Stud­
ies Depression Scale (CES-D), measures of satisfaction 
with several domains of life experience, and a popula­
tion-specific physical symptoms questionnaire. In 
both groups, the overall SIP score as well as the scores 
on its physical and psychosocial dimensions improved 
continuously after transplantation, reaching levels 
that are comparable to those found in the general 
population. The occurrence of acute or chronic rejec­
tion had a significantly negative effect on SIP and 
CES-D scores. Intention-to-treat analysis showed no 
differences between groups for scores on SIP, ABS, 
CES-D, and satisfaction measures. Exclusion of 41 pa­
tients who did not strictly adhere to their originally 
designated therapy showed a tendency for better psy­
chosocial SIP scores in CsA patients (P=0.05), which 
mainly resulted from a difference on the category of 
social interaction (P—0,01). This difference occurred 
despite a similar rejection rate and worse renal func­
tion in CsA-treated patients. Shortly after steroid 
withdrawal, a high proportion of CsA patients com­
plained of stiff or painful muscles (CsA: 74%, Aza-Pred: 
36%; P=0.002). Our data indicate that if successfully 
completed, CsA monotherapy from 3 months after 
transplantation may lead to a higher degree of psycho­
social well-being as compared with conversion from 
CsA-Pred to Aza-Pred. It seems likely that this advan­
tage is related to the withdrawal of Pred.
One of the primary goals of renal transplantation is to 
improve the quality of life of the patient with end-stage renal 
disease. Traditional research efforts, however, have mainly 
been directed at prolonging patient and graft survival. These 
survival rates have improved considerably during the last 
decades and any further progress will be hard to achieve. 
Therefore, it is not surprising that the quality of life of the 
patients with prolonged survival is receiving a growing 
amount of attention (i, 2).
The type of immunosuppressive drug therapy is one of the
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factors that determine the quality of life after renal trans­
plantation. First, an effective immunosuppressive regimen, 
leading to prolonged patient and graft survival, is a prereq­
uisite to reach an optimal level of quality of life. Besides, 
treatment schedules may act more directly on quality of life 
by means of their adverse effects, which will differ according 
to the drugs that are used. Patients’ psychosocial function­
ing, which they will partly attribute to prescribed medica­
tion, will in turn have influence on the compliance with tho 
therapeutic regimen (3). Eventually, compliance is one of the' 
main determinants of long-term graft survival (4 - 7).
Our aim was to investigate the impact of the currently 
most frequently used immunosuppressive drugs on changes 
in quality of life during the first year after renal transplan­
tation. Health-related quality of life was therefore measured 
in participants in a randomized prospective trial comparing 
cyclosporine (CsA)* monotherapy with the combination of 
azathioprine (Aza) and prednisone (Pred) from 3 month« 
after renal transplantation.
PATIENTS AND METHODS
Patient population . From July 1989 to June 1992, all adult 
patients who underwent a first or second cadaveric renal transplan­
tation at our institution were invited to take part in this study. 
Patients were excluded when they fulfilled one or more of the follow­
ing exclusion criteria: age above 65 years, history of psychiatric 
disease or alcohol abuse, history of malignancy, poor knowledge of 
Dutch language, signs of active hepatitis or carriage of hepatitis B 
surface antigen, hemolytic uremic syndrome as original kidney dis­
ease, use of anti-epileptic drugs, and allergy to Aza. After surgery, 
patients were treated with CsA and Pred for 3 months. Afterward, 
they were randomly allocated to CsA monotherapy or to the combi” 
nation therapy of Aza and Pred. At 3 months after transplantation, 
59 of the 186 patients who initially entered the study could not bo 
randomized to a treatment arms for one of the following reason«: 
patient death or graft loss in the first 3 months after transplantation 
(n=39), loss of patient to follow-up (n = l), contraindication for CbA 
by clinical judgment (usually because of signs of CsA nephrotoxicity; 
n=16), use of Aza contraindicated because of bone marrow depres­
sion (n—2), and use of Pred contraindicated because of severe 
osteoporosis (n= l).
Stu dy protocol. CsA was given intravenously (3 mg/kg/d ay) for 
the first 3 days after surgery followed by 12 mg/kg/d ay in 2 divided 
oral doses during the first month. This dosage was gradually re du cod 
to 4 mg/kg/day at 3 months after transplantation. The dosage was 
adjusted to maintain CsA trough blood levels between 200 and 400 
ng/ml. Prednisolone was given at a dose of 100 mg/day iv , during the* 
first 2 days after surgery, followed by an oral Pred dosage of 25 
mg/day during the remainder of the first month and 20 mg/day
* Abbreviations: ABS, Affect Balance Scale; ATG, antithymocylu 
globulin; Aza, azathioprine; CES-D, Center of Epidemiological 
Studies Depression Scale; CsA, cyclosporine; Pred, prednisone; SIP, 
Sickness Impact Profile.
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during the second and third month after transplantation. In patients 
who were randomized to receive CsA monotherapy, CsA was contin­
ued in the same dosage, with adjustments to reach trough blood 
levels between 100 and 200 ng/ml. The daily Pred dosage was re­
duced by 5 mg every 2 weeks, resulting in CsA monotherapy after 6 
weeks. In patients allocated to Aza-Pred therapy, CsA was replaced 
without overlap by Aza at a dosage of 3 mg/kg. Their Pred dosage was 
temporarily increased from 20 to 25 mg/day and reduced by 5 mg 
every 2 weeks until a maintenance dose of 10 mg/day was reached. In 
the CsA group, Pred was restarted if  more than 1 acute rejection or 
chronic vascular rejection occurred after randomization. The same 
conditions led to replacement of Aza by CsA in the Aza-Pred group. 
In case of severe and persistent side effects, attributable to one of the 
drugs, patients were put on the alternative treatment regimen.
During the first 3 months after transplantation, acute rejection 
episodes were treated with methylprednisolone (1 g i.v. on 3 consec­
utive days) or antithymocyte globulin (ATG; RIVM Bilthoven, The 
Netherlands; 200 mg i.v. on alternate days for 10 days). An oral 
course of high-dose Pred (initial dosage 200 mg/day tapering to 25 
mg/day in 12 days) was given after failure of one or both of these 
treatments,
From 3 months after transplantation (i.e., after randomization), 
acute rejections were treated primarily with ATG in all cases. High» 
dose Pred courses were given in case of failure of ATG, bone marrow 
suppression, or previous treatment with ATG for rejection.
Hypertension, defined as diastolic blood pressure above 95 
mmHg on 3 consecutive occasions, was treated in a standard way 
using a /3-blocker (atenolol), followed by the successive addition of 
a calcium antagonist (nifedipine) and a diuretic (chlorthalidone) 
when necessary.
Quality of life measurements (see below) were carried out at 3 
months (i.e., before randomization) as well as at 6 and 12 months 
after transplantation. Body weight and blood pressure as well as 
results from routine clinical chemistry were recorded at regular 
intervals as part of the usual posttransplant patient evaluation. 
Body mass ( Que tele t) index was calculated as weight in kg divided by 
the square of the height in meters. Creatinine clearance was 
estimated with the formula given by Cockcroft and Gault (S).
The study was approved by the Hospital Ethics Committee and all 
patients gave written informed consent.
Q uality o f  life assessm ent. Questionnaires were administered by a 
single trained interviewer who was not aware of medical data of the 
patients, including their type of treatment. The questionnaire con­
sisted of both generic measures and of questions rather specific for 
the population of renal transplant patients. The generic measures 
comprised the Sickness Impact Profile (SIP), the Affect Balance 
Scale (ABS), the Center of Epidemiological Studies Depression Scale 
(CES-D), and questions on satisfaction with several domains of life 
experience. The SIP measures sickness-related behavioral dysfunc­
tion and contains 136 items that can be divided into 12 categories (9). 
Three categories can be aggregated into a physical dimension (am­
bulation, mobility, and body care and movement), 4 categories make 
up a psychosocial dimension (social interaction, alertness behavior, 
communication, and emotional behavior), and 5 categories are inde­
pendent (eating, work, home management, sleep and rest, and rec­
reation and pastimes). Total scores and scores on the various cate­
gories and dimensions are expressed on a scale of 0 to 100, with 
higher scores denoting worse state. The Dutch version of the SIP that 
we used has been validated (10). The ABS contains 10 questions on 
positive and negative feelings during the past few weeks (11). Scores 
on the ABS can vary from 1 to 9, with higher scores indicating a more 
favorable grade of well-being. The CES-D is another standardized 
measure of affect. It is composed of 20 items that result in a score 
which increases along with a more depressive state from 0 to 60 (12). 
In addition to these composite scales, the questionnaire asked for 
overall life satisfaction and for satisfaction with 4 domains of life 
experience, derived from the study of Campbell et al. (13). We added 
2 items questioning satisfaction with, sexual activities and with the
renal transplantation. The complete list of domain satisfaction mea­
sures is given in Appendix A. Finally, the questionnaire contained a 
set of physical symptoms, a number of them being rather specific for 
the population of renal transplant patients (Appendix B). Most of 
these items were gathered from various other studies. Retesting of 
validity and responsiveness of this disease-specific questionnaire 
was not considered necessary (14).
Statistical analysis. All data were analyzed with the SAS system 
(SAS Institute Inc.» Cary, NC). Because the majority of data were not 
normally distributed, data are given as medians, with interquartile 
range in brackets. Unpaired comparisons of numerical data between
2 groups at different time points were carried out with Wilcoxon's 
rank sum test. Proportions were compared with chi-square analysis 
using continuity correction. Paired comparisons of numerical and 
ordinal data within 1 group were performed with Wilcoxon’s signed 
rank test. Simple correlations were assessed by calculating Spear­
man’s correlation coefficient. A P-value smaller than 0.05 was con­
sidered statistically significant.
RESULTS
Full evaluation of the data was not possible in 7 of the 127 
patients who were allocated to the treatment groups. Two 
patients (1 in each treatment group) died between 3 and 12 
months after transplantation. Two patients (both in the CsA 
group) were not able to respond to the questionnaire at 6 
months after transplantation because of severe illness. Two 
more patients (1 in each group) discontinued their participa­
tion. Finally, in 1 case (Aza-Pred group), the interviewer 
judged the answers as highly unreliable.
The demographic and clinical characteristics of the re­
maining 120 patients are shown in Table 1. There were no 
significant differences between the treatment groups.
Intention-to-treat analysis. Graft loss occurred once in 
each group between 3 and 6 months after transplantation. To 
perform an intention-to-treat analysis, these patients were 
not excluded and they completed the questionnaires while 
having returned to hemodialysis. The main clinical results of 
the transplantation are given in Table 2. As expected, renal 
function improved after conversion from CsA to Aza in the 
Aza-Pred group. This resulted in a significant difference be­
tween groups at 12 months after transplantation. The num­
ber of patients with 1 or more acute rejection episodes after 
randomization (i.e., between 3 and 12 months after trans­
plantation) was 25 (42%) in the CsA group and 16 (27%) in 
the Aza-Pred group (NS). Chronic rejection was observed in 
15 patients (CsA: 10, Aza-Pred: 5; NS) and was only twice not 
preceded by any acute rejection episode. None of the other 
parameters that may influence quality of life showed a sig­
nificant difference between groups. The time course of scores 
on the SIP, ABS, and CES-D is given in Table 3. A continu­
ous, significant improvement of SIP scores took place be­
tween 3 and 12 months after transplantation in both groups. 
Neither the actual values nor the degree of improvement of 
any score differed significantly between treatment groups. 
Acute rejection, chronic rejection, or both were diagnosed in 
43 patients between 3 and 12 months after transplantation. 
Their quality of life during this interval (i.e., at 6 months 
after transplantation) appeared worse than in nonrejecting 
patients (Table 4). In the whole group, there was a negative 
correlation between creatinine clearance and total SIP score 
(at 3 months #= -0 .41 , P<0.001; at 6 months £= -0 .21 , 
P=0.02; at 12 months R  = —0.24, P =0.009). After exclusion of 
patients who experienced acute or chronic rejection, this
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Table 1. Characteristics of patients who were treated with CsA monotherapy or Aza and Pred from 3 months after renal
transplantation0
All patients (n=120) CsA (n=60) Aza-Pred (n=60)
Sex (M/F) 76/44 38/22 38/22
Age (yr) 43(29-53) 43(32-53) 42(28-54)
First/second Tx 98/22 48/12 50/10
Time on dialysis (mo) 23(13-38) 25(12-43) 23(14-38)
Diabetes mellitus 1 1 0
Marital status
Unmarried, living alone 31 12 19
Married/living together 83 43 40
Widowed 3 2 1
Divorced 3 3 0
Living situation
Alone 10 4 6
Living with partner/spouse only 38 19 19
Living in a family 60 31 29
Otherwise 12 6 6
Highest level of education
Basic school 14 5 9
Lower vocational training 45 24 21
Higher vocational training 23 10 13
Lower general secondary education 16 11 5
Higher general secondary education 8 3 5
College 14 7 7
Salaried position 34 18 16
a Numerical data are given as medians with interquartile ranges.
Table 2. Clinical results at 3 months (before randomization) and 12 months after renal transplantation in patients allocated to CsA
monotherapy (n=60) or treatment with Aza and Pred (n=60)
3 Months 12 Months
CsÀ Aza-Pred CsA Aza-Pred
numbers (%)
At least 1 acute rejection 16 (27) 16 (27) 34“ (57) 29" (48)
Chronic rejection ---------- --------- 10 (17) 5(8)
Antihypertensive therapy 44 (73) 44 (73) 39 (65) 39 (65)
medians (interquartile ranges)
Body mass index (kg/m2) 23.7 23.3 25.56 25.06
(21.3-25.6) (21.5-25.8) (22.6-27.1) (22,0-27.7)
Weight gain after Tx (%) 3.3 4.3 10.00 8.6Ò
(“ 0.3-9.2) (-0 .1 -7 .7 ) (3.7-16.9) (4.1-12,8)
Creatinine clearance (ml/min) 57 52 53 64ò,c
(40-69) (42-66) (43-67) (53-84)
Hemoglobin (mmol/L) 7.2 7.0 8.16 8.1*
(6.3-7.7) (6.7-7.S) (7.3-8.8) (7.3-8.6)
a Including rejections that occurred during the first 3 months.
b P < 0.001 for difference with values of the same treatment group at 3 months after transplantation, 
c P < 0.001 for difference with CsA group.
correlation remained significant at 3 months (#= —0.37, 
P<0.001), but had disappeared at 6 and 12 months after 
transplantation.
Per-protocol analysis. In 39 patients, the initially assigned 
treatment had to be changed for a variety of reasons. Pred 
was added to CsA in 7 patients because of the occurrence of 
more than 1 acute rejection or chronic rejection episode after 
steroid withdrawal. In another 6 patients, steroid with­
drawal was not completed for a variety of reasons. CsA was 
replaced by Aza in 12 cases, all but once because of CsA- 
induced renal dysfunction. In 2 patients, Aza was replaced by 
CsA because the patients had a second acute rejection 
episode after prior conversion from CsA to Aza. Bone marrow 
depression and liver function disturbances prompted switch­
ing from Aza to CsA in 8 and 4 additional patients, respec­
tively. After exclusion of both this group of 39 patients and 
the 2 patients with graft loss, 79 patients (CsA: n=34, Aza- 
Pred: n=45) remained available for per-protocol analysis.
The clinical results of the transplantation in this subgroup 
of patients are given in Table 5. There was no significant 
difference between treatment regimens in the incidence of 
acute rejection episodes after randomization (CsA: 10/34 
[29%], Aza-Pred: 9/45 [20%]). Regarding quality of life mea­
sures, the treatment groups did not differ significantly in 
actual values at any time point nor in changes over time 
(Table 6). Nevertheless, there was a trend toward a persis­
tently better score on the psychosocial dimension of the SIP 
in the CsA monotherapy group. Of the 4 categories that make
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Table 3. Scores on SIP, ABS, and CES-D at 3, 6, and 12 months after renal transplantation in patients allocated to CsA monotherapy
(n=60) or treatment with Aza and Pred (n=60)a
3 Months 6 Months 12 Months
CsA Aza-Pred CsA Aza-Pred CsA Aza-Pred
SIP
Total* 9.1 8.7 5.8C 5.3d 3.8C 3.5e
(5.5-16,4) (3.6-16.5) (3.7-11.4) (2.1-14.4) (1.3-6.5) (0.5-10.4)
Physical0 5.7 4.1 1.9d CO ÒÌ ft 0.8C 1.2e
(1.5-12.9) (1.0-13.9) (0-10.1) (0-10.7) (0-4.4) (0-6.7)
Psycho soci al 4.5 4.3 1.9d 4.8 1.3* 3.1e
(1.6-14.7) (1.9-14.4) (0-6.9) (0-12.3) (0-4.0) (0-9.7)
ABS 7 6 7 7 7.5 7
(6-8) (5-8) (5.5-8) (5-8) (6-8,5) (5.5-8)
CES-D* 2 2 2.5 2.5 Ie 1
(0.5-7) (0-6) (1-6) (0-9) (0-4) (0-5.5)
fl Data are given as medians with interquartile ranges, 
b Lower scores on these indexes indicate better quality of life.
c PcO.OOl for difference with values of the same treatment group at 3 months after transplantation. 
d P<0,01 for difference with values of the same treatment group at 3 months after transplantation. 
eP<0.05 for difference with values of the same treatment group at 3 months after transplantation.
Table 4. Scores on SIP, ABS, and CES-D at 3, 6, and 12 months after renal transplantation in patients with (n=43) and without (n=77)
diagnosis of acute or chronic rejection between 3 and 12 months after transplantation, irrespective of treatment group0
Acute/chronic rejection 3-12 mo
3 Months 6 Months 12 Months
Yes No Yes No Yes No
SIP
Total0 9.5 8.7 8.7 4.4c,d 4.0e 3 5 c>d
(4.5-16.0) (4.8-16.4) (3.5-14.7) (2.0-10.7) (1.8-11.0) (0.4-6,8)
Physical6 5.9 3.8 5.2 1.2c'rf 1.& 0.8*
(2.2-14.4) (0.8-12.3) (0-13.4) (0-9.1) (0-10.2) (0-3,9)
Psychosocial^ 4.2 4.6 4.2 1.9e 3.3f 1.3rf
(1.4-14.9) (1.9-13.9) (0-12.4) (0-8.1) (0-8.3) (0-5.1)
ABS 7 7 7 7 7 7'
(6-8) (5-8) (6-8) (5-8) (5-8) (6-9)
CES-D* 2 2 3 2 2 Ie
(0-7) (0-6) (0-7) (0-6) (0-6) (0-4)
c Data are given as medians with interquartile ranges. 
b Lower scores on these indexes indicate better quality of life,
CP<0.05 for difference with patients with rejection.
d P < 0.001 for difference with values of the same group at 3 months after transplantation, 
eP<0.01 for difference with values of the same group at 3 months after transplantation. 
^P<0.05 for difference with values of the same group at 3 months after transplantation.
up this psychosocial dimension, only the social interaction 
category showed different scores between groups at 6 months 
(CsA: 0 [0-3.6], Aza-Pred: 3.6 [0-15*2]; P=Q.04) and 12 
months (CsA: 0 [0-3*6], Aza-Pred; 3>5 [0-7.9]; P=0.01). None 
of the 20 individual items within the social interaction 
category displayed significant differences.
There were no differences in the ratings on the various 
satisfaction measures. At 1 year after transplantation, only 1 
(CsA-treated) patient was slightly dissatisfied with life in 
general. Also, 1 (Aza-Pred) patient expressed some dissatis­
faction with his renal transplantation. On the other hand, 8 
patients (CsA: 3/31 [10%], Aza-Pred: 5/37 [14%]; NS) were to 
some extent (score 5 or higher) dissatisfied with their sex life.
For the evaluation of the incidence of physical symptoms, 
we interpreted a score of 1 as absence and a score of 2 or 
higher as presence of the concerning symptom. Table 7 gives 
the incidence of the 10 most frequent complaints in either
group at the various time points, completed by items at which 
significant differences were observed.
Subgroup analysis for males and females, respectively, did 
not demonstrate differences between treatment groups on 
any quality of life index. Analysis of subgroups according to 
age, with the median age (41 years) as partition, disclosed a 
significant difference on the psychosocial dimension of the 
SIP for older patients at 1 year after transplantation (CsA: 0
[0-1.4], Aza-Pred: 2*4 [0-9.3]; P=0.03).
Finally, to avoid possible bias by an unequal rejection 
incidence in both groups, we analyzed the data after exclu­
sion of patients who experienced acute or chronic graft rejec­
tion after randomization (CsA: 10/34, Aza-Pred: 10/45). At 6 
months after transplantation, CsA-treated patients again 
tended to have better scores on the psychosocial dimension of
the SIP (CsA: 0 [0-4.3], Aza-Pred: 4.9 [0-16.9]; P=0.06),
with significant differences for its social interaction (CsA: 0
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T able  5. Clinical results at 3 and 12 months after renal transplantation in patients treated with CsA monotherapy (n=34) or Aza and
Pred (n=45)°
3 Months 12 Months
CsA Aza-Pred CsA Aza-Pred
numbers (%)
At least 1 acute rejection 8(24) 12 (27) 16*(47) 206 (44)
Chronic rejection — -- 0 3 (7)
Antihypertensive therapy 25 (74) 35 (78) 19 (56) 29 (64)
medians (interquartile ranges)
Body mass index (kg/m2) 23.6 23.2 25.5C 25.0C
(21.9-25.5) (21.6-25.6) (22.8-26.9) (22.3-27.7)
Weight gain after Tx (%) 2,1 4.3 9.6C 9.4C
(-0.6-10.0) (0.3-9.5) (4,8-13.3) (4.1-X2.5)
Creatinine clearance (ml/min) 58 51 55 QQC,d
(46-71) (42-64) (48-64) (56-85)
Hemoglobin (mmol/L) 7.3 7.0 8.2C 8.1°
(6.4-7.8) (6.6-7.7) (7.7-8.8) (7.S-8.6)
° Patients who deviated from their originally assigned treatment were excluded,
6 Including rejections that occurred during the first 3 months,
CP<0.001 for difference with values of the same treatment group at 3 months after transplantation. 
d P<0.001 for difference with CsA group.
TabliD 6. Scores on SIP, ABS, and CES-D at 3, 6, and 12 months after renal transplantation in patients treated with CsA monotherapy
(n=34) or Aza and Pred (n=45)a
3 Months 6 Months 12 Months
CsA Aza-Pred CsA Aza-Pred CsA Aza-Pred
SIP
Total6 7.5 9.4 5.5C 5.2rf 2.4* 3.2e*
(5.3-10.1) (4.8-17.7) (3.5-8.8) (2.1-121) (0.5-5.4) (0.4-8.0)
Physical6 4.0 4.7 1.5 1.9e 0d 0.8^
(0.8-10.2) (1.0-15.1) (0—8.6) (0-9.9) (0-3.3) (0-4.0)
Psychosocial6 3.5 5.6 1.4 4.9/ 3.1d'*
(0-9.9) (3.0-17.1) (0-5.3) (0-10.1) (0-2.8) (0-9.3)
ABS 7 6 7 7 7.5 T
(6-8) (5-8) (6-8) (5-8) (6-8) (6-8)
CES-D6 2 2 2 3 Ie 1
(0-5) (1-7) (1-5) (0-9) (0-4) (0-5)
a Patients who deviated from their originally assigned treatment were excluded, Data are given as medians with interquartile ranges. 
b Lower scores on these indexes indicate better quality of life,
c P<0.05 for difference with values of the same treatment group at 3 months after transplantation. 
d P<0.001 for difference with values of the same treatment group at 3 months after transplantation. 
e P<0.01 for difference with values of the same treatment group at 3 months after transplantation.
^P=0.06 for difference versus CsA group.
8 P =0.05 for difference versus CsA group.
[0-3.6], Aza-Pred: 3.6 [0-15.4], P-0,02) and emotional 
behavior (CsA: 0 [0-0], Aza-Pred: 0 [0-16.2]; P=0.04) 
categories.
DISCUSSION
Our study population demonstrated an ongoing improve­
ment of quality of life during the first year after transplan­
tation, as measured with the SIP. Previous, cross-sectional 
studies established a higher quality of life in transplanted 
patients when compared with patients on hemodialysis or 
continuous ambulatory peritoneal dialysis (15-17), while a 
few prospective studies have reported a rise in health status 
after successful transplantation (18,19). Our results indicate 
that the figures obtained in renal graft recipients depend on 
the time elapsed after transplantation. Assuming that the 
transplant procedure itself will have been responsible for a 
transient drawback in quality of life, it probably takes at
least a year to reach the optimal posttransplant level. Al­
though a number of patients at this time still obviously 
suffered from physical disabilities and complications, the 
achieved ratings for quality of life were extremely high. Total 
SIP scores at 1 year after transplantation were comparable to 
the mean score of 3.4 that was obtained in a sample of the 
general Dutch population (10). The majority of patients (77%) 
rated 1 or 2 on the 7-point scale for overall life satisfaction. 
Similar observations were made before in renal (2> 15-17) 
and liver transplant patients (20,21). The favorable scores in 
these patient groups have been attributed to the feeling of 
being reborn after transplantation, to the desire to fulfill 
certain expectations, and to psychological defense mecha­
nisms against fear for rejection and complications (21).
During the first year after transplantation* the occurrence 
of rejection episodes had a clear deteriorating effect on qual­
ity of life. Physical complaints related to the rejection process
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Table  7. Presence of physical complaints at 3, 6, and 12 months after renal transplantation in patients treated with CsA monotherapy
(n-34) or Aza and Pred (n=45)a
3 Months 6 Months 12 Months
CsA Aza-Pred CsA Aza-Pred CsA Aza-Pred
Excessive hair growth 76 64 59* 24c,d 32d
*
rjc.d
Swollen face 62 58 12* 33d 9 20d
Need for rest 59 58 65 49 35 42
Feeling tired 59 56 65 44" 47 49
Excessive appetite 50 58 Qd n d f i s d
m
18d
Trembling hands 56 53 I8d i s b I2d 4d
Too fat 47 44 47 44 44 42
Feeling weak 35 42 35 27 15 22e
Stiff or painful muscles 41 42 74* 36c 35 31
Tingling in hands 26 38 15 166 12* grf
Headache 32 27 18 31 18 18
Swollen ankles 24 18 26 16 15 13
Feeling sick 26 24 24 29 15 20
Problems to sleep on 24 33 24 20 9e 16
Shortness of breath 21 24 18 31 15 16
Problems to fall asleep 21 24 24 22 21 16
Bruises 24 20 15 29 9 33^
Heartburn 15 13 6 20 9 22
Dizziness 9 16 0 2 <f 6 13
“ Patients who deviated from their originally assigned treatment were excluded. Data are given as percentages. 
6 P<0.01 for difference with scores at 3 months after transplantation. 
c P<0.01 for difference with CsA group.
d PcO.OOl for difference with scores at 3 months after transplantation. 
e P<0.05 for difference with scores at 3 months after transplantation, 
f P <0.05 for difference with CsA group.
or worse graft function, side effects of antirejection treat­
ment, and being faced with a serious setback may all have 
been responsible for the impaired quality of life. Unfortu­
nately, our data do not allow firm conclusions on the degree 
of reversibility of this phenomenon after successful treat­
ment of acute rejections.
We found no difference in quality of life between our 2 
treatment groups. Both groups were similar on demographic 
variables that have been shown to correlate with total SIP 
score, such as age, sex, education, and length of time with 
end-stage renal disease (17). Theoretically, any difference 
should be caused by disparate effects of both treatment reg­
imens on factors such as graft survival, rejection rate, and 
graft function, or, more directly, by a different array of ad­
verse effects. In our intention-to-treat analysis, especially the 
latter, possible cause of differences could be obscured by the 
fact that departure from the originally designated drug ther­
apy occurred in about one third of the patients. Since both 
treatment regimens were explicitly designed to have no drug 
in common (CsA vs. the combination of Aza and Pred), we 
excluded those patients who did not keep to their originally 
assigned treatment and subsequently performed a per-proto­
col analysis. Again, no significant differences could be dem­
onstrated in the measured parameters of quality of life. The 
slightly higher rejection rate and the worse renal function 
(both associated with a decline in quality of life) in the CsA 
monotherapy group did not result in a less favorable score on 
any measure. In fact, there was a tendency for a more ben­
eficial score on the psychosocial dimension of the SIP in these 
patients, with statistical significance being reached in the 
older half of the population. A significant difference on the 
social interaction category appeared to be mainly responsible
for this finding. We can only speculate about an explanation 
for this difference. Lack of the steroid-related appearance 
may have offered the opportunity for the CsA-treated pa­
tients to visit their family and friends more frequently as 
well as feel themselves more comfortable in contacts with 
other people. Based on existing knowledge of the effects of 
corticosteroids on affect and mood ("steroid high”), differ­
ences could have been expected on the CES-D and the SIP 
emotional behavior category. Although improvements on 
these measures did not differ between groups, scores on the 
latter item were superior in the CsA monotherapy group 
after exclusion of patients with acute or chronic rejection.
Ratings on satisfaction measures were quite high in both 
groups. Notably, the lowest levels of satisfaction were re­
corded in the sexual life domain. Sexual problems are well 
recognized in dialysis patients (22), but this issue apparently 
deserves attention after renal transplantation too. For sev­
eral physical symptoms, a marked improvement between 3 
and 12 months after transplantation was observed. The 
higher incidence of hypertrichosis in the CsA group and the 
higher incidence of increased appetite and bruises in the 
Aza-Pred-treated patients were not unexpected. A remark­
ably high number of CsA-treated patients complained of 
muscle pain and stiffness during the first few months after 
withdrawal of steroids. In some of the patients, these com­
plaints were so severe as to urge extended continuation of 
low doses of Pred, which led to relief of symptoms.
To our knowledge, only once before has quality of life been 
reported as an outcome variable in a randomized clinical trial 
in renal transplant patients (2). In that study, comparing 
CsA-Pred with the regimen of antilympho cyte globulin fol­
lowed by Aza-Pred, quality of life was also assessed at 1 year
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after transplantation, although, baseline measurements were 
not performed. Patients on CsA-Pred appeared to fare better 
on indicators of physical, emotional, and social well-being, 
but the differences lost statistical significance after correc­
tion for the higher number of rejections and infections in the 
Aza-Pred group. Nonetheless, there remained a tendency for 
a more favorable score on some measures of emotional well­
being in the CsA-Pred patients, who used lower Pred doses 
than their counterparts in the Aza-Pred group. Our finding of 
a slightly better score on the psychosocial dimension of the 
SIP in CsA patients, in spite of a rejection rate which at least 
equaled that in Aza-Pred patients, adds to this observation. 
Taken together, these results indicate that lowering the dose 
or withdrawal of prednisone may improve rather than 
worsen the quality of life after renal transplantation.
For both the changes over time as well as the effect of 
rejection on quality of life, the SIP appeared to be our most 
sensitive measuring instrument. This fits in with the high 
figures for accuracy and reproducibility that have been re­
ported for this questionnaire in various circumstances (9,23). 
Nevertheless, the discriminative capacity of the SIP, and of 
the ABS and CES-D as well, was impeded by the fairly high 
quality of life in this population. Therefore, it can be ques­
tioned whether the lack of differences between the treatment 
groups may reflect a type II error, also in connection with the 
limited size of our patient population. Because of little expe­
rience with this type of research in the field of transplanta­
tion, we did not have reliable information (e.g., on the ex­
pected distribution of the data and meaningful sizes of 
differences) needed to perform a proper power analysis before 
the start of the study.
Although the importance of measuring the quality of life is 
generally appreciated (1, 24), the skeptical reader may ask 
whether it adds any information to what can be derived from 
usual clinical judgment and laboratory figures. In this re­
gard, it was instructive that measured parameters of quality 
of life improved substantially in our CsA-treated patients 
between 3 and 12 months after transplantation; during this 
interval, 42% of them experienced one or more acute rejection 
episodes, and their renal function did not improve at all. 
Therefore, we believe it is useful to incorporate quality of life 
measurement in future trials concerning the treatment of 
organ transplant recipients.
APPENDIX A
Set of Satisfaction Measures
Respondents were asked to rate their satisfaction with 
each item on a 7-point scale ranging from completely satis­
fied (1) to completely dissatisfied (7). If an item did not apply 
for the patient in case, it was skipped.
• In general, how satisfied are you with your life as a whole 
these days?
• How satisfied are you with the attention and support that 
you receive from family or surroundings?
• How satisfied are you with your marriage or relation­
ship?
• How satisfied are you with your sexual life?
• How satisfied are you with your daily pursuits and inter­
ests?
• How satisfied are you with your physical condition?
• In general, how satisfied are you with the renal trans­
plantation?
APPENDIX B 
S e t o f  Q u estion s on P h y s ic a l  C o m p la in ts
Respondents were asked to rate each item on a scale of 1 to 
4, with 1 = not at all and 4 = very much.
Regarding the past week,
• did you have a need for rest?
• were you feeling sick?
• were you feeling weak?
• did you feel tired?
• were you feeling physically well?
• did you have trouble with falling asleep?
• did you have problems to sleep on?
• did you have loss of appetite?
• did you suffer from nausea?
• did you have to vomit?
• did you consider yourself too fat?
Regarding the past week, did you suffer from:
• stiff, tender, or painful muscles?
• a swollen face?
• abdominal pain?
• diarrhea?
• constipation?
• dizziness, feeling faint?
• loss of sight?
• a skin disorder?
• shortness of breath?
• headache?
• swollen ankles?
• burning eyes?
• stomachache?
• heartburn?
• excessive appetite?
• trembling hands?
• bruises?
• a tingling feeling in hands or fingers?
• excessive hair growth?
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NORMALIZATION OF CIRCADIAN BLOOD PRESSURE PROFILES 
AFTER RENAL TRANSPLANTATION
C h r is to p h  D. G a tz k a ,1 H a n s P. S c h o b e l, A r n fr ie d  U. K lin g b e il, H a n s  H . N eu m a y er, and
R o la n d  E. S c h m ie d e r
Department o f Internal Medicine IV-Nephrology, University o f Erlangen-Nürnberg, D-90471 Nürnberg, Germany
Most patients with secondary hypertension due to 
renal disease or on maintenance hemodialysis have 
lost the physiologic fall of blood pressure during sleep. 
To test the notion that kidney transplantation normal­
izes the blood pressure profile, we monitored ambula­
tory blood pressure over 24 hr in 45 patients (29 males 
and 16 females) after successful renal transplantation.
The longer the time after renal transplantation, the 
more marked was the decrease of blood pressure dur­
ing sleep (r=0.38, P<0.01). This effect of time after 
renal transplantation on the fall of blood pressure dur­
ing sleep was independent of the prevailing level of 
24-hr ambulatory blood pressure. The prevalence of 
dippers (defined by a fall in mean blood pressure dur­
ing sleep of 10% or more of the awake mean) increased 
from 27% in the early phase (< 7 months) to 73% in the
1 Address correspondence to: Dr. Christoph D. Gatzka, Depart­
ment of Internal Medicine IV-Nephrology, University of Erlangen- 
Nürnberg, Breslauer Str. 201, D-90471 Nürnberg, Germany.
late phase (s  1 year) after renal transplantation 
(P<0.01). Again, this effect was not attributable to the 
level of 24-hr ambulatory blood pressure and concom­
itant antihypertensive or immunosuppressive medica­
tion.
We conclude that renal transplantation leads to a 
normalization of the circadian blood pressure profile 
with a marked decrease of blood pressure during 
sleep. As a consequence, the lower hemodynamic load 
imposed on the cardiovascular system may in turn 
lead to a reduction of cardiovascular morbidity and 
mortality.
In normotensive subjects as well as in patients with mild to 
moderate essential hypertension, blood pressure (BP)* falls 
by 15-25% during sleep (the “dipper” pattern) (1, 2). In con­
trast, in patients with secondary hypertension, this decrease
* Abbreviations: BP, blood pressure; MAP, mean arterial pres­
sure; RT, renal transplantation.
